Literature DB >> 34808386

Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development.

Tixiao Wang1, Jie Zhang1, Na Li1, Mengzhen Li1, Shuaiya Ma1, Siyu Tan1, Xiaowei Guo1, Zehua Wang1, Zhuanchang Wu1, Lifen Gao1, Chunhong Ma2, Xiaohong Liang3.   

Abstract

The spatial organization of immune cells within the tumor microenvironment (TME) largely determines the anti-tumor immunity and also highly predicts tumor progression and therapeutic response. Tim-3 is a well-accepted immune checkpoint and plays multifaceted immunoregulatory roles via interaction with distinct Tim-3 ligands (Tim-3L), showing great potential as an immunotherapy target. However, the cell sociology mediated by Tim-3/Tim-3L and their contribution to tumor development remains elusive. Here, we analyzed the spatial distribution of Tim-3/Tim-3L in TME using multiplex fluorescence staining and revealed that despite the increased Tim-3 expression in various tumor-infiltrated lymphocytes, Tim-3+CD4+ cells were more accumulated in parenchymal/tumor region compared with stromal region and exhibited more close association with patient survival. Strikingly, CD4 T cells surrounding Tim-3L+ cells expressed higher Tim-3 than other cells in cancerous tissues. In vivo studies confirmed that depletion of CD4 T cells completely abrogated the inhibition of tumor growth and metastasis, as well as the functional improvement of CD8 T and NK, mediated by Tim-3 blockade, which was further validated in peripheral lymphocytes from patients with hepatocellular carcinoma. In conclusion, our findings unravel the importance of CD4 T cells in Tim-3/Tim-3L-mediated immunosuppression and provide new thoughts for Tim-3 targeted cancer immunotherapy.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Tim-3; Tim-3 ligands; immune checkpoint blockade; multiplexed immunofluorescence; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34808386      PMCID: PMC8899527          DOI: 10.1016/j.ymthe.2021.11.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy.

Authors:  Catherine A Sabatos-Peyton; James Nevin; Ansgar Brock; John D Venable; Dewar J Tan; Nasim Kassam; Fangmin Xu; John Taraszka; Luke Wesemann; Thomas Pertel; Nandini Acharya; Max Klapholz; Yassaman Etminan; Xiaomo Jiang; Yu-Hwa Huang; Richard S Blumberg; Vijay K Kuchroo; Ana C Anderson
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

2.  Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages.

Authors:  Wenjiang Yan; Xiao Liu; Hongxin Ma; Hualin Zhang; Xiaojia Song; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Gut       Date:  2015-01-21       Impact factor: 23.059

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 4.  Immunological hallmarks of stromal cells in the tumour microenvironment.

Authors:  Shannon J Turley; Viviana Cremasco; Jillian L Astarita
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

5.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

6.  Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection.

Authors:  Ying Ju; Nan Hou; Xiao Ning Zhang; Di Zhao; Ying Liu; Jin Jin Wang; Fang Luan; Wei Shi; Fa Liang Zhu; Wen Sheng Sun; Li Ning Zhang; Cheng Jiang Gao; Li Fen Gao; Xiao Hong Liang; Chun Hong Ma
Journal:  Cell Mol Immunol       Date:  2009-02       Impact factor: 11.530

Review 7.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

Review 8.  Intratumoral heterogeneity in cancer progression and response to immunotherapy.

Authors:  Ilio Vitale; Efrat Shema; Sherene Loi; Lorenzo Galluzzi
Journal:  Nat Med       Date:  2021-02-11       Impact factor: 87.241

Review 9.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.

Authors:  Shuang Qin; Linping Xu; Ming Yi; Shengnan Yu; Kongming Wu; Suxia Luo
Journal:  Mol Cancer       Date:  2019-11-06       Impact factor: 27.401

10.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Authors:  Matthew D Hellmann; Luis Paz-Ares; Reyes Bernabe Caro; Bogdan Zurawski; Sang-We Kim; Enric Carcereny Costa; Keunchil Park; Aurelia Alexandru; Lorena Lupinacci; Emmanuel de la Mora Jimenez; Hiroshi Sakai; Istvan Albert; Alain Vergnenegre; Solange Peters; Konstantinos Syrigos; Fabrice Barlesi; Martin Reck; Hossein Borghaei; Julie R Brahmer; Kenneth J O'Byrne; William J Geese; Prabhu Bhagavatheeswaran; Sridhar K Rabindran; Ravi S Kasinathan; Faith E Nathan; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

View more
  3 in total

Review 1.  Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.

Authors:  Adrià Archilla-Ortega; Carla Domuro; Juan Martin-Liberal; Purificación Muñoz
Journal:  J Exp Clin Cancer Res       Date:  2022-02-14

2.  A novel immune-related radioresistant lncRNAs signature based model for risk stratification and prognosis prediction in esophageal squamous cell carcinoma.

Authors:  Jianqing Zheng; Xiaohui Chen; Bifen Huang; Jiancheng Li
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

Review 3.  Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?

Authors:  Christian Bailly; Xavier Thuru; Bruno Quesnel
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.